Swiss pharma major Novartis (NOVN: VX) has reported that its oral candidate remibrutinib significantly cut relapse rates ...
Medicines regulators in major international markets have issued a run of first-in-class approvals, safety communications, ...
French biotech firm Inventiva (Euronext: IVA) has appointed Chris Benecchi as chief operating officer, completing its ...
US biotech major Amgen has announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk adults ...
Sino-American oncology-focused biotech BeOne Medicines has announced positive top-line results from the second interim ...
Immunic, a late-stage biotech developing oral therapies for neurological diseases, has appointed Chitrang Davé as chief data ...
Swiss pharma giant Novartis said its Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib met their primary endpoint, ...
RedHill Biopharma today announced the transformational acquisition of exclusive global and US commercialization rights to ...
The 2026 theme is "Data to Dialogue: Communicating Radiotherapy's Value to Advance Care". The 68th annual meeting runs from ...
Waltham, Massachusetts-based advanced therapy contract development and manufacturing organization (CDMO) and gene editing services provider ElevateBio has announced the appointment of Steven Falcone ...
Beam Therapeutics, a Cambridge, Massachusetts-based biotech developing precision genetic medicines through base editing, announced Tuesday the appointment of Eric Foster as chief commercial officer ...
The US Food and Drug Administration has approved Besremi (ropeginterferon alfa-2b-njft) injection for the treatment of adults with essential thrombocythemia, from Taiwan-based PharmaEssentia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results